AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Status:
Not yet recruiting
Trial end date:
2033-02-04
Target enrollment:
Participant gender:
Summary
The investigators propose a Phase I/IB trial for patients with advanced stage, uterine serous
or high grade endometrioid tumors. The trial will include a dose escalation phase of 6-24
patients to define the maximum tolerated dose of AVB-500 in combination with standard-of-care
paclitaxel. The trial will also include a dose expansion phase of 12 patients. Additionally,
all patients will be consented and approached for 13C-glucose (13C is a stable,
non-radioactive isotope) infusion before biopsy for metabolomic assays. Tumors and biopsies
will be assessed by immunohistochemistry to identify potential biomarkers of response.